Considering the underlying mechanisms of COVID-19 and the documented advantages of SGLT2 inhibitors and GLP1RA, these treatments may offer unique benefits compared to other therapies for individuals with type 2 diabetes mellitus (T2DM) and long COVID-19 and potentially even for those without diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.